Did you know that stroke ranks as the world's second major cause of mortality, culminating in over 6 million fatalities annually?*
The forefront of stroke deterrence hinges on bespoke medicine, with therapies fine-tuned to the individual. Clopidogrel, a pivotal P2Y12 inhibitor, stands paramount in forestalling recurrent strokes amongst those at elevated risk. Yet, the drug's efficacy is notably contingent upon one's genetic constitution.
Genetic evaluations grant critical insights into a person's clopidogrel responsiveness, thus enabling healthcare practitioners to refine therapeutic decisions. This mitigates ischemic event risks. By pinpointing individuals harboring specific genetic discrepancies that impede clopidogrel's activation, personalized medicinal tactics can sculpt efficacious stroke prevention modalities, elevating patient prognoses.
This discourse delves into the utility of genetic assessments in enhancing stroke preventio...
_____
If you are a member of our Association, please log in below to continue reading our exclusive content.
Not a member yet? Discover the benefits of joining our network and gain access to exclusive content like this for only $29.95 per month. Learn More and Sign Up
